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Abstract

The main objectives of this study are to review existing methodologies for
projecting future trends in contraception, evaluate the validity of the assumptions
underlying these projections, propose methodological improvements, and assess the
prospects for new methods of contraception in the coming decade. The prevalence
of contraception in the developing world has increased sharply over the past several
decades from near zero in 1960 to around 60 percent in 2000. Demand for contraception can be expected to continue to rise rapidly for the next few decades as population size continues to grow and fertility declines further to near the replacement
level. As a result of these trends the number of users of contraception in the developing world is expected to rise from 549 million to 816 million over the next 25 years
according to the most recent UN projection. An examination of the projection methodology found it to be reasonable. The rate of growth in users will be much more
rapid in Africa than in Asia or Latin America.
Projecting the future distribution of specific contraceptive methods is more
difficult. Method choice is affected by trends in several factors, including access to
different methods, user characteristics, and technology. The procedures employed
by the Futures Group to project the method mix were found to be less than optimally
designed and a new methodology was therefore proposed. The general approach is
one of slow and incomplete convergence toward a more balanced method mix in
each country, with uniform reductions in the role of traditional methods. The new
alternative projections to 2015 are quite different from those made by the Futures
Group. For example, for the developing world as a whole the proportions relying on
female sterilization are higher in 2015 (37 percent rather than 26 percent), and proportions using traditional methods are lower (7 percent instead of 14 percent).
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Contraceptive behavior in the developing world has changed markedly over the
past three decades. Around 1960 only a tiny fraction of couples practiced contraception,
and knowledge of methods was very limited. In contrast, contraceptive knowledge is
now widespread and more than half of married women in the developing world are
current users of contraception. The large majority of these users rely on modern methods, including male and female sterilization, the IUD, and the pill. This revolution in
contraceptive behavior has been driven by a desire to reduce family size, as social and
economic changes have increased the cost of children and reduced their benefits. Another key factor contributing to this rise in contraception has been the diffusion of information about and access to contraceptive methods, aided by a rapid expansion of family
planning programs. This expansion of access to a range of methods has helped couples
implement their preferences for smaller families and avoid unwanted pregnancies.
While past trends in contraceptive behavior are fairly well established, there is
uncertainty about what lies ahead. Because contraceptive prevalence levels among married women of reproductive age in many developing countries are approaching levels
often found in the industrialized world, one might conclude that contraceptive demand
is about to level off. Although future increases in contraceptive use could well occur at
a slower pace than heretofore, a further expansion of demand is likely for two reasons.
First, the fertility transition in the developing world is not yet complete. The average
number of children per woman has declined from six to three since 1960, but this still
leaves fertility about 50 percent above the replacement level of about two children that
is expected to prevail in the long run. These further fertility declines will almost certainly be achieved by additional increases in the practice of contraception. Second, as
population growth continues, the number of women of reproductive age (15–49 years)
is expected to rise in most developing countries. These two factors will drive up the
number of users of contraception in the developing world for the next few decades. In
contrast, the demand for contraception in the industrial world will likely see little rise in
aggregate because neither the level of fertility nor the number of women in the reproductive ages is expected to change much from current levels. However, in specific countries prevalence could rise, in particular where levels of abortion are high (e.g., in Eastern Europe and Japan). In addition, the method mix could well change substantially in
both the industrial and the developing world. Such a change would occur even if no
additional methods are made available, and it will likely be accelerated by the prospect
of new contraceptive technologies.

To assess prospects for future trends in contraceptive use, projections have been
made recently by the United Nations (1999a) and the Futures Group (Ross et al. 1999).
The UN projects numbers of users for different world regions from 1993 to 2025. The
Futures Group provides similar results for individual developing countries to 2015, and
also projects numbers of users of different methods. The main objectives of this paper
are to review the methodologies used in these projections, evaluate their results, propose methodological improvements, and assess the prospects for new methods of contraception in the coming decade. Before analyzing these projections we summarize past
trends because they provide the basis for the projections. The focus throughout is on the
developing world.
L EVELS AND T RENDS IN C ONTRACEPTIVE
P REVALENCE AND M ETHOD M IX
Prevalence
Figure 1 plots estimates of contraceptive prevalence (i.e., the percentage practicing a method among women who are married or in union) for the developing and industrial worlds as well as for selected regions for the latest available year, 1993 (UN 1999a).
For the developing world as a whole, prevalence in 1993 stood at 55 percent. This is 15
percentage points less than the estimate of 70 percent for the industrial world in the
same year. The developing-world average is heavily influenced by the high prevalence
in China (83 percent); without China, this average would have been only 43 percent.
Sharp differences between regions are evident, with prevalence ranging from 20 percent
in Africa to 66 percent in Latin America. If, as seems likely, fertility has continued to
decline since 1993, then prevalence today should be a few percentage points higher than
in 1993. In fact, the developing-world average (including China) in 2000 is estimated at
60 percent (UN 1999a).
Past trends in contraceptive prevalence for 98 developing countries are plotted in
Figure 2. Each line in this figure represents one country with two or more observations
per country. A full discussion of this set of detailed data is not attempted here, but a few
conclusions can be drawn: 1) In the early 1990s prevalence levels varied from a few
percent in several African countries to over 75 percent in a small number of countries in
Asia and Latin America (Brazil, China, Hong Kong, and South Korea). 2) There has
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Figure 1 Level of current contraceptive use by region, ca. 1993
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Figure 2 Trends in contraceptive prevalence among married women, by country
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been a pervasive upward trend in prevalence over the past quarter-century. This trend is
evident in most countries into the 1990s, except in populations where prevalence remains low (mostly in sub-Saharan Africa). 3) The number of countries for which prevalence estimates are available is greatest in the late 1980s and early 1990s and decreases
for earlier dates. The relatively small number of countries with estimates for the 1960s
and 1970s tend to be selected for higher-than-average prevalence (UN 1999a). It is therefore difficult to obtain unbiased estimates of global and regional averages for the past. It
is possible to obtain indirect estimates through backward projection, but this approach
has not been implemented systematically (Bongaarts 1984).
Contraceptive methods
Methods of contraception practiced today include “modern” and “traditional”
ones. Modern refers to clinic and supply methods such as voluntary surgical sterilization, IUD, pills, injectables, condoms, and vaginal barrier methods. The main traditional
or nonsupply methods are periodic abstinence and withdrawal as well as traditional folk
methods with uncertain efficacy. Figure 3 (right bar) presents estimates of the method
mix for the most recent available date (ca. 1993) for the developing world. Sterilization
(mostly female) accounts for nearly half of all contraceptive use. Other modern methods
(mostly IUDs and the pill) account for most of the remainder, while only 9 percent of
women rely on traditional methods. This mix of methods has changed only modestly
over time. Since 1980, the proportion of users relying on sterilization and injectables (a
new method) has increased, and the pill, IUD, and other methods have become correspondingly less prevalent (UN 1996).
The mix of methods varies considerably among regions and countries. Users in
Africa are much less likely to have been sterilized than their counterparts in Asia and
Latin America, and they are more likely to rely on the pill or traditional methods. Sterilization is about equally common in Asia and Latin America, but in Asia the prevalence
of the IUD is much higher and pill use lower than in Latin America.
At the country level, variation in method mix is even greater than at the regional
level. This is illustrated in Figure 4, which presents levels and past trends for one method—
female sterilization—for 98 countries. The proportion of users relying on female sterilization ranges from a tiny percentage in a few countries (mostly in Africa) to well over
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Figure 3 Percent distribution of contraceptive methods used by married women, by region,
ca. 1993
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Figure 4 Trends in the proportion of users relying on female sterilization, by country
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half in India (67 percent) and over half in Brazil (52 percent) and a few other Latin
American countries. Aside from this variation in levels there is also variation in past
trends in the proportion of women sterilized, but no pervasive upward or downward
trend is evident in the data plotted in Figure 4 from the mid-1980s onward. A similarly
wide range exists in relative levels of use of other methods (data not shown). As was the
case for female sterilization, in a few countries more than half of all use is accounted for
by a single method. This is the case for the pill in Algeria (83 percent), Morocco (64
percent), and Zimbabwe (69 percent) and for the IUD in Egypt (63 percent) and Vietnam (51 percent). Among the main reasons for the heavy reliance on a single method in
these countries are an emphasis on that method in family planning programs and limited
availability of providers of other methods in the private sector. There is little doubt that the
method mix would be less skewed in these countries if couples were given a wider choice.
F UTURE T RENDS IN C ONTRACEPTIVE P REVALENCE
AND N UMBERS OF U SERS

Results from recent projections
As noted above, the United Nations and the Futures Group have prepared projections of the number of contraceptive users and contraceptive prevalence. The main results of these exercises are summarized in Table 1. In 1993, the base year of the UN’s
projection, the number of users in the developing world was estimated at 436 million.
By 2000 this total had grown to an estimated 549 million. Over the next quarter-century
the UN expects a further increase of 49 percent to 816 million in 2025. The corresponding regional projections indicate a far larger increase in Africa (254 percent) than in Asia
(28 percent) or Latin America (37 percent).
The projections of contraceptive prevalence among married women are presented
in panel B of Table 1. For the developing world as a whole the UN estimates prevalence
in 2000 at 60 percent (up from 55 percent in 1993), and in 2025 prevalence is expected
to reach 67 percent. The current sharp regional differences in prevalence are expected to
moderate considerably, with very rapid increases in Africa’s prevalence from 29 percent
in 2000 to 55 percent in 2025. Smaller increases are projected for Asia and Latin America,
reaching 69 percent and 73 percent respectively over the next quarter-century.
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Table 1 Projections of numbers of contraceptive users and contraceptive prevalence
by region and source
Percent increase
A. Number of contraceptive users (million)
Source

1993

2000

2015

2025

2000–
2015

2000–
2025

Africa

UN

26

47

111

167

135

254

Asia

UN

357

437

544

560

24

28

Latin America

UN

53

65

83

89

28

37

UN

436

549

738

816

34

49

525

742

Developing world

Futures Group

41

B. Contraceptive prevalence (percent among women in union)
Source

1993

2000

2015

2025

Africa

UN

20

29

46

55

Asia

UN

60

64

69

69

Latin America

UN

66

70

72

73

Developing world

UN

55

60

65

67

58

66

Futures Group

Note: Asia excludes Japan, Australia, and New Zealand.
Source: UN 1999a and Ross et al. 1999.

The projections by the Futures Group up to 2015 also indicate substantial increases in the number of users and in prevalence. However, the UN and Futures Group
differ significantly in a number of key respects. For example, the Futures Group’s estimates of the number of users for the year 2000 is lower than the corresponding number
for the UN (525 vs. 549 million, a difference of 24 million or 4 percent). The cause of
this difference is difficult to pinpoint in the absence of country-specific estimates from
the UN, but one of the main reasons appears to be a lower Futures Group estimate of the
number of users in China. Another notable difference between the two projections is
that Futures expects the number of users to increase by 41 percent between 2000 and
2015, compared to a rise of 34 percent projected by the UN. These results are due to
differences in projection methodology, which will be explored further below.
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Why the number of users keeps rising
An obvious cause of future increases in the number of users in the developing
world is the rise in contraceptive prevalence that presumably will accompany anticipated further declines in desired fertility. Several other variables, however, also affect
the future number of users. Specifically, the projected growth in contraceptive users
over any time interval in any country is attributable to changes in one or more of the
following five factors:
P = Population size
F = Proportion of P that is female aged 15–49
M = Proportion of F that is married/in union
C = Proportion of M that practices contraception (i.e., prevalence)
T = Ratio of all users (married and unmarried) to married users.
The number of users (U) at any point in time is the product of these five factors:
U = P x F x M x C x T.
For example, the number of users in the developing world in 2000 is estimated by the
UN at 549 million, which equals 4867 x 0.26 x 0.71 x 0.60 x 1.03. The corresponding
equation for the projected number of users in 2025 is 6609 x 0.25 x 0.68 x 0.67 x 1.08 =
816 million. The growth in the number of users from 549 million to 816 million over
this 25-year period is therefore attributable to increases in population size, P (from 4867
to 6609 million), contraceptive prevalence, C (from 0.60 to 0.67), and the ratio of all
users to married users, T (from 1.03 to 1.08). These trends are partly offset by small
declines projected in the proportion of the population female and 15 to 49, F (from 0.26
to 0.25) and in the proportion married, M (from 0.71 to 0.68).
The specific contributions of the factors (P, F, M, C, and T) to future increases in
the number of users can be measured by comparing the percent increase or decrease in
each over the projection period 2000 to 2025. These estimates are provided in Table 2.
For the developing world as a whole, the number of users is projected to be 48.6 percent
higher in 2025 than in 2000. This rise is largely attributable to anticipated increases in
population size (35.8 percent) and in contraceptive prevalence (12.6 percent). The re-
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Table 2 Projected percent change (2000–2025) for components of growth in the number of contraceptive users, by region
Percent change 2000–2025
Population
size
P

Africa
Asiaa
Latin America
Developing world

65.5
29.5
34.2
35.8

Proportion
female
Proportion
15–49
married
F
M

10.8
–5.8
–5.0
–3.1

–4.2
–3.8
4.2
–3.9

Contraceptive
prevalence
C

Total
married
T

Total

85.2
9.2
4.2
12.6

8.7
0.0
–0.9
4.3

253.7
28.1
37.2
48.6

a

Excludes Japan, Australia, and New Zealand.
Source: Derived from data in UN 1999a.

maining factors F, M, and T have substantially smaller effects (–3.1, –3.9, and 4.3 percent, respectively) and they partly offset one another. This same analysis of the roles of
different factors has been conducted separately for Africa, Asia, and Latin America (see
Table 2). Future increases in population size and contraceptive prevalence are also the
dominant causes of future increases in users in each region. This is especially the case in
Africa, where the huge expected increase in the number of users (253.7 percent) is much
higher than the average for the developing world. This difference between Africa and
other regions is attributable primarily to much more rapid-than-average increases in
population size (65.5 percent) and in prevalence (85.2 percent).
A comment on projection methodology
A projection of the future number of users in a population can be made by preparing separate projections for each of the variables P, F, M, C, and T. The procedures
employed by the UN and Futures Group for forecasting these factors directly or indirectly are complex but broadly similar. They both rely on the UN’s standard projections
of population size and the proportion female and 15–49 (UN 1999b). Estimates of future
proportions of women currently married differ slightly (the UN assumes a small decline
while the Futures Group holds this proportion constant) and the future trend in the ratio
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of total users to the number of married users is similar.1 However, the two agencies
differ significantly in the way future trends in contraceptive prevalence are projected,
and a brief comment on this difference is in order.
The UN and the Futures Group both assume that future trends in prevalence can
be derived from future trends in fertility and that the level of fertility will change (mostly
decline) over time as predicted in the standard UN population projections. Given these
assumptions, the question is how to turn a fertility trend that is presumed known into a
contraceptive prevalence trend.
The Futures Group’s procedure for projecting prevalence trends is based on the
well-established close statistical relationship between levels of prevalence and fertility
(as measured by the total fertility rate, TFR). Figure 5 plots the relationship for these
variables in 98 developing countries. Each line in this figure represents one country and
connects the prevalence and fertility levels observed in all past years for which estimates are available in that country. The level of correlation between fertility and prevaFigure 5 Relationship between contraceptive prevalence and the total fertility rate,
by country
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lence is clearly high (r=0.90), which is not surprising since the practice of contraception
is the main proximate determinant of fertility (Bongaarts and Potter 1983). Variations
around the regression line in Figure 5 are due to measurement errors as well as to variations in a number of other proximate determinants that also influence fertility (e.g., the
proportion of women in union and the propensity to rely on induced abortion). It is also
evident from the figure that the lines representing the different past country experiences
generally run parallel to the regression line. This implies that, as expected, a decline in
fertility is almost always accompanied by a rise in prevalence. There is some convergence to the regression line as prevalence rises—that is, the variation around the regression line declines at lower levels of fertility. The Futures Group relies on these features
to estimate future trends in prevalence from fertility trends.
The key assumption made by the Futures Group is that all countries move over
the course of the projection from the level of prevalence measured at the latest post1980 survey to a prevalence level of 72.5 percent when the TFR reaches 2 births per
woman. This endpoint for the projection is located on the regression line and is illustrated as point A in Figure 6. For example, a country located at point B in Figure 6 in
2000 (TFR=3, C= 50 percent) at the beginning of the projection is expected to move
along a linear trajectory toward point A (TFR=2, C=72.5 percent) during the projection.
In other words, any country that is now located above or below the regression line is
expected to be on this line when the TFR reaches 2 births per woman at some future
time. The rate at which a country moves along this trajectory over time depends on the
trend in the total fertility rate (which is taken from the standard UN population projections). If a country’s TFR does not decline to 2 by 2015, it completes only part of the
trajectory and prevalence remains below 72.5 percent in 2015.
The UN’s procedure is more complex and, among other things, takes into account differences in contraceptive effectiveness. However, the basic principle on which
it is based is easily demonstrated for a hypothetical country with an average level of
contraceptive effectiveness. The UN assumes that such a country moves over time from
its current level of prevalence and fertility toward a prevalence level of 100 percent
when the TFR reaches zero births per woman.2 For example, a country located at point
B in Figure 6 in 2000 (TFR=3, C= 50 percent) would move along a linear trajectory
toward point C (TFR=0, C=100 percent). Since no country is expected to reach zero
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Figure 6 Illustrative projected trends in contraceptive prevalence by level of fertility
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fertility, only part of the path BC is traversed by countries over the next quarter-century.
In general, the UN projects a slightly lower future level of prevalence than the Futures
Group for countries that are located below the regression line at the beginning of the
projection and a somewhat higher trajectory for those that start above this line. Since
there are roughly as many countries above as below the regression line, the average
trend for the two projections is similar.
For most countries the procedures followed by the two organizations provide
plausible projections. The results are generally similar for countries that fall on or near
the regression line at the start of the projection. The main differences occur in countries
that are near the end of the fertility transition but are still some distance from the regression line (e.g., point D in Figure 6). In such cases the Futures Group procedure typically
projects a fairly sharp change in the trend (path DA) compared with the past, while the
UN’s projection (path DC) represents a smoother transition. The UN also takes into account
differences in contraceptive effectiveness and assumes modest improvements in effectiveness over time. These desirable features should improve the accuracy of UN’s projections.
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F UTURE T RENDS IN C ONTRACEPTIVE M ETHOD
D ISTRIBUTION
Results from recent projections
The Futures Group is the only organization that makes projections of the distribution of contraceptive methods used by women. According to these projections substantial changes will occur in the method mix by 2015 (see Table 3). For the developing
world as a whole, at least a doubling is expected between 1993 and 2015 for the proportion of users relying on the condom (from 4 to 10 percent) and the pill (from 11 to 22
percent). Increases are also expected for traditional methods (from 9 to 14 percent),
injectables (from 4 to 6 percent), and vaginal methods (from 0.3 to 0.6 percent). However, substantial declines are forecast by 2015 for the proportion relying on female sterilization (from 39 to 26 percent), male sterilization (from 8 to 3 percent), and for the
IUD (from 26 to 18 percent).

Table 3 Estimates of method distribution in 1980 and 1993 and alternative projections
for 2015
Projections
Past Estimates
Method
Female sterilization
Male sterilization
Pill
Injectablesa
IUD
Vaginal
Condom
Traditional
Total

1980

Futures Group

New procedure b

1993

2015

2015

24
13
13
0
32
0
5
12

39
8
11
4
26
0.3
4
9

26
3
22
6
18
0.6
10
14

37
5
17
5
20
0.4
9
7

100

100

100

100

a

Includes Norplant®.
See Appendix for discussion.
Source: UN 1996, 1999a; Ross et al. 1999.
b
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These projections indicate a continuation of past trends (1980–93) for the IUD,
male sterilization, and vaginal methods, but for all other methods the Futures Group
expects reversals of past trends. Some of these results are surprising, especially the
sharp drop in female sterilization and the rise in traditional methods. There are no obvious reasons to expect such large reversals. In our view, these projections are not optimally designed in some respects, and we will propose changes in the projection procedures. Before turning to these methodological issues we briefly describe the factors that
might affect trends in method choice.
Determinants of method choice
The mix of contraceptive methods selected by couples who wish to avoid pregnancy will continue to evolve in response to changes in several factors:
Improved access. In many developing countries potential users have a very limited choice of methods. A main reason for this is that program managers often emphasize just one or two methods, largely to reduce costs, thus restricting the user’s options
in countries where national family planning programs are the dominant source of contraceptive supplies. For example, the copper IUD is inexpensive and provides highly
effective contraception for up to a decade. Female sterilization and the pill are also
commonly made available through national programs. Regulatory barriers often contribute to limited use of some methods. In a number of countries choice is so limited that
the majority of users must rely on a single method. Examples of this situation are the
dominance of female sterilization in India, of the IUD in Egypt and Vietnam, and of the
pill in Algeria, Morocco, and Zimbabwe. It is plausible to assume that with a general
move toward a market economy and greater emphasis on quality of care, the choices
available to potential users will increase in the future.
Changing characteristics of users. Knowledge of contraception has increased
enormously in recent decades. In most countries women and men are fairly well informed about different methods and their costs, side effects, benefits, and sources of
supply. Higher levels of education also have made users more assertive, a trend that
should lead to improvements in services. Another important trend with implications for
the selection of methods is a continuation of the decline in desired family size. In con-
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temporary pretransitional societies women often want large families and, as a consequence, demand for contraception is low and focused on methods for spacing births
rather than limiting them. This situation has characterized much of sub-Saharan Africa
until recently (Caldwell et al. 1992; Westoff and Bankole 1995). However, as countries
develop, desired family size declines and the demand for limiting family size rises sharply.
Permanent methods are often used by women who want no more children. Over the next
few decades these trends toward lower desired family size and increasing proportions of
women who want no more children can be expected to continue. This, in turn, will lead
to a high future demand for long-acting methods. In the past these women have often
relied on sterilization, but the irreversible nature of this method is an important drawback. There clearly is a need for new methods that are inexpensive, long acting, safe,
and reversible.
New and improved technology. Among the available methods, users select the
ones that are least costly, most convenient, most effective, and that have the fewest
health and other side effects. This explains why traditional methods were largely abandoned in the 1960s and 1970s when modern methods became widely available. Around
90 percent of users in the developing world now rely on modern methods, and in most
countries the proportion of users relying on traditional methods will no doubt continue
to decline. The availability of new and improved technology is likely to lead to further
changes in method use in future decades. This topic is discussed in greater detail in the
last part of this paper.
Trends in these three general factors will result in future changes in the mix of
methods used by couples in the developing world. Although changes will vary from
country to country, it is likely that in most countries the dominant methods will become
somewhat less prevalent and the other less-used methods will rise in prevalence. It is
important to note, however, that such changes typically occur rather slowly.
A comment on methodology
A full discussion of the methodology employed by the Futures Group is beyond
the scope of this paper. Instead, we illustrate the main features of the projection procedure for one method—female sterilization. Figure 7 plots the Futures Group’s projec-
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Figure 7 Projections by the Futures Group of the proportion of users relying on female
sterilization for countries expected to reach low fertility by 2015
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Source: Ross et al. 1999.

tions to 2015 of the proportion of users relying on female sterilization for all countries
that are expected to complete the fertility transition by 2015. The key feature of the
methodology is clear from the patterns in this figure: most countries move from their
current level of female sterilization to an average just above 30 percent. In other words,
regardless of the current level, each of these countries moves either up or down toward
the same level by 2015 (populations still in transition by 2015 move only partway to this
endpoint). This pattern applies to a majority of countries, but a second smaller group
consisting solely of Muslim countries is assumed to converge to a lower average of
around 7 percent. Finally, for a third set of countries, special projections were made in
ways that are not specified (see Ross et al. 1999 for details).
How reasonable are these procedures used by the Futures Group? Since the accuracy of projections cannot be assessed a priori, it is not possible to ascertain whether
particular assumptions about the future are valid. However, the procedure seems less
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than optimally designed. Specifically, while some convergence toward an average can
be expected, there is no evidence for rapid convergence in the late 1980s and early
1990s, just as no convergence was seen earlier in Figure 4 for female sterilization. In
addition, an inspection of the new projections to 2015 for individual countries reveals
some surprising and probably unrealistic future trends that result from this assumed
rapid convergence. For example, between 2000 and 2015 the proportion of users relying
on female sterilization is projected to decline from 63 percent to 32 percent in India,
from 28 percent to 7 percent in Pakistan, and from 15 percent to 7 percent in Bangladesh. Another question is raised by the assumed trends in the role of traditional methods. Although the Futures Group projects declines in the proportion of traditional methods in the majority of countries, it also projects increases for a substantial number. For
example, in China this proportion is expected to rise from 2 percent to 17 percent between 2000 and 2015. Such increases seem unlikely. This large projected increase in
China and the expected rising proportion of all users who live in Africa (where traditional methods are relatively common) are the main causes of the upward trend in traditional methods projected by the Futures Group for the developing world as a whole by
2015 (see Table 3).
An alternative projection
The preceding comments suggest the following desirable characteristics for a
methodology that projects the method mix within countries. First, convergence to a
more balanced method mix is likely to occur, but it seems important to allow for considerable inertia. In the past the distribution of methods changed only slowly over time in
most countries and the mix at one point in time was highly correlated with the mix 10 or
15 years later.3 In the Futures Group’s procedure this correlation largely disappears between 2000 and 2015. Second, countries will not all reach the same method distribution
in 2015. A range of historical, cultural, socioeconomic, and other factors have contributed to the preference of some methods over others in the past. Although such preferences might well diminish in the future, they will almost certainly not disappear altogether. Third, there seems to be little justification for using different projection procedures
for different groups of countries. Instead, the fact that a country has a particular charac-
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teristic (e.g., Muslim) can be considered as one of several factors that lead to current
preferences for a particular mix in that country. This preference should be maintained to
some degree in the future. Fourth, declines in traditional methods can be expected in the
future and this trend should be explicitly acknowledged.
These proposed features have been incorporated into a simple new projection
procedure, which we describe in the Appendix. The general approach is one of slow and
incomplete convergence toward a more balanced method mix in each country, with uniform reductions in the role of traditional methods. All countries are treated in the same
way. The main results of the application of this new methodology are presented in the
last column of Table 3. As expected, these alternative projections to 2015 are quite different from those made by the Futures Group. For the developing world as a whole the
proportions relying on female sterilization are higher in 2015 (37 percent rather than 26
percent), and the proportions using traditional methods are lower (7 percent instead of
14 percent). Trends for individual countries are also quite different. For example, a more
modest decline in female sterilization is forecast for India (from 67 percent to 53 percent
rather than to 32 percent), and increases are expected in Pakistan (from 28 percent to 32
percent) and in Bangladesh (from 15 percent to 25 percent) rather than declines to 7
percent. These trends seem plausible, although any projection is subject to potentially
substantial errors.
The simple alternative procedure presented here should be considered to be no
more than a first step toward a detailed and comprehensive methodology for projecting
method distribution. Given the scant attention in the literature to the causes of variation
in method mix, it is not clear which refinement would improve the accuracy of these
projections. Further methodological developments will no doubt benefit from more indepth studies of the factors affecting choice of methods in specific countries (see Potter
1999 for an excellent example).
P ROSPECTS FOR N EW C ONTRACEPTIVE T ECHNOLOGY
A new method requires many years to gain general acceptance, because the contraceptive market moves slowly and is conservative4 (see Figure 8). For example, the
first market approval of a copper IUD occurred in 1971, but almost two decades passed
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Figure 8 Time line of the development of modern contraceptives
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before the device became the most widely used contraceptive after female sterilization.
During this period, the copper IUD was greatly improved both in efficacy and duration
of use. A similarly slow evolution has occurred in the case of oral contraceptives. The
oral contraceptive available to women worldwide in 2000 is very different from the pill
first introduced in the United States in the 1960s. The dosage has been drastically reduced, the steroids used are different, and the greater knowledge of the pill’s biological
effects enables providers to counsel users more thoroughly.
From a market perspective, female sterilization and vasectomy differ from the
other modern methods because sterilization is not a product provided by any manufacturer. The development of improved surgical methods has reduced the surgical trauma
and time required for the procedure. However, the efficacy and safety of sterilization are
largely dependent on the skill of the provider and the quality of the institutions offering
the supporting services, such as anesthesia, blood supply, and sterilization of the surgi-
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cal instruments. The individual user can do very little to improve the outcome of the
procedure. Unfortunately, sterilization is sometimes the only long-term contraceptive
available.
In most countries, women are increasingly able to choose good alternative contraceptives developed during the last two decades. There are now four long-term reversible contraceptive products that are virtually as effective as female sterilization. Table 4
lists their generic and trade names, protection times, and approximate number of users
worldwide.5
1) The copper IUD is the most commonly used long-term reversible contraceptive, and the most affordable one ever developed. The cost of the device when bought in
large quantities from the manufacturer is very low (around US $1.00). In fact it is unlikely that any long-term method with such low cost per year of protection will ever be
developed again. The IUD with greatest efficacy is the copper T 380A. This method is
convenient, but increases menstrual blood loss and menstrual pain. The hormonal methods, on the other hand, reduce these side effects.
2) Norplant®, the first hormonal implant developed for female contraception, has
been found acceptable in most cultures. Having gained approval in 60 countries including the United States, Norplant is effective and safe but requires trained providers for
both insertion and removal. Its main disadvantage for the user is unpredictable vaginal
bleeding, which, however, tends to be light and is accompanied by little or no pain. A
number of new hormonal implant methods are expected to become available in the near
future (see Table 5). Jadelle® consists of two levonorgestrel rods that offer effective
Table 4

Characteristics of currently available long-term contraceptives

Method

Trade name

Copper T 380A
6 levonorgestrel-filled
Silastic® capsules
Levonorgestrel intrauterine
system
Medroxyprogesterone
acetate 150 mg i.m.a
a

Use time

Million users

Paragard®

10–12 years

30–40

Norplant®

7 years

8

Mirena®

5 years

1

3 months

12

Depo Provera®

By intramuscular injection
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pregnancy protection for up to five years. Jadelle has been approved in the United States
and Finland, and wider European approval is pending. Implanon® consists of one
ketodesorgestrel rod with proven efficacy for up to three years. Implanon is approved in
Europe and Indonesia, while approval in the United States is pending. Nestorone®-one,
a single implant that offers protection for two years, is still in the pipeline. It is specially
designed for use during lactation and does not affect the nursing infant. A single rod
containing gestodene is under development in China, and a nomegestrol acetate Silastic®
implant (Uniplant®) with a lifespan of one year is pending approval in Brazil.
3) Mirena® is a levonorgestrel-releasing intrauterine system that is highly effective for at least five years. It also provides significant health benefits, including drastic
reduction of pain and blood loss during menstruation, as well as reduction in uterine
pathology. Menstrual blood loss is reduced by more than 90 percent, an important characteristic for use in developing countries, where anemia is a widespread health problem.
Mirena is now widely accepted in Europe after introduction in 1990 in Scandinavia. It is
particularly popular among women who are dissatisfied with existing methods and those
who are candidates for female sterilization. Mirena may also be used to treat excessive
menstrual bleeding and to protect the uterus from the effects of estrogen therapy during
and after menopause.
4) Injectable contraceptives are likely to occupy a fairly small niche among contraceptive systems. This category is currently dominated by Depo Provera®, which provides three months of contraception per injection, but longer-lasting systems are in development. A monthly injectable, Lunelle®, has just been launched in the United States

Table 5

Current global development status of implants for contraception
Number of
implants

Use
experience

Norplant®

6

10 million

60 countries

5–7

Schering AG, Wyeth

Jadelle®

2

studies

US, Finland

3–5

Schering AG, Wyeth

Implanon®

1

studies

Europe, Indonesia

2–3

Organon

Nestorone®-one

1

studies

phase 3

2

Population Council

Uniplant®

1

studies

pending in Brazil

1

South-to-South

Name

Approval
status
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Effectiveness
(years)

Sponsor

and is quite popular in Mexico. Lunelle is the only injectable contraceptive associated
with a predictable bleeding pattern.
Long-term hormonal contraceptive use is likely to grow in the future. Mirena is
being introduced in developing countries, and the monthly injectable is already popular
in Latin America. Within our time frame (2015), cost will be a limiting factor for widespread use of hormonal contraception in developing countries. However, with extensive
use in the developed world, the cost is likely to decrease. The popularity of these contraceptives will also depend on a shift in attitude toward changes in menstrual bleeding
patterns. Long-term hormonal methods reduce menstrual blood loss—for example, by
50 percent with the use of Norplant (Fraser et al. 2000) and by more than 90 percent
with Mirena (Andersson and Rybo 1990)—and in some women monthly bleedings are
eliminated altogether. In northern Europe, women’s attitudes regarding menstruation
are changing rapidly. Even among young women, menstrual bleeding is considered a
nuisance (den Tonkelaar and Oddens 1999). Educated women have also learned that the
monthly bleedings produced by oral contraceptives have nothing to do with the normal
menstrual cycle because they are caused by the discontinuation of the pill. The timing of
these bleedings, therefore, may be manipulated at will. Women in Europe also realize
that the collecting of menstrual blood is a cumbersome procedure that limits their mobility and social life (Kristjansdottir et al. 2000). However, the liberation of women
from the burden of menstruation will likely be slow—following improvements in education and in the availability of methods that reliably suppress bleeding. Predictability
will be the main selling point. Unfortunately, most currently available methods generally offer poor predictability for women.
Other hormonal methods now under development are expected to become available in the next decade. Hormonal contraception will soon be available in the form of
patches, utilizing the transdermal route of administration with a mode of action similar
to that of oral contraception. A weekly patch is likely to improve compliance, the lack of
which is the main drawback of oral contraceptives. In the foreseeable future, women
will be able to choose vaginal rings that provide hormonal contraception in much the
same way as oral contraceptives, but without the first-pass metabolic effects on the liver
that occur with oral delivery. In clinical trials vaginal rings give excellent bleeding control and are well accepted by women.
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Emergency contraceptives in the form of hormones or copper IUDs will be widely
used in the future. Copper IUDs are very effective in preventing a pregnancy up to five
days after unprotected coitus. Hormonal tablets are less effective and should be taken as
soon as possible after coitus. In the next decade specially designed emergency contraceptives will be on the market; these new products will be more effective and will have
fewer side effects. Widespread availability and use of emergency contraceptives are
likely to reduce the need for induced abortions.
We expect that medical abortion will become much more widely available within
a few years. Mifepristone in combination with misoprostol is now widely used for medical abortion in China. Mifepristone was approved by the French government in 1988, by
the European regulatory agency in 1999, and by the FDA in September 2000. It will be
distributed in the United States under the trade name Mifeprex®. Medical abortion with
these substances is safe and will greatly reduce mortality and morbidity associated with
both induced and spontaneous abortions in developing countries.
Vaginal microbicides that protect women from sexually transmitted infections,
including HIV, are high on the list of needed products. Many such compounds are in
early development, but none to date has entered efficacy trials. Microbicides could be
combined with spermicides to have a contraceptive effect as well. Microbicides will
provide greater protection for women, many of whom currently have to negotiate condom use with their sexual partners.
Research on the development of male hormonal contraceptives has accelerated
recently and several methods are in the late stages of development. Aside from birth
control, hormonal contraceptives may provide other health benefits in men, as hormonal
contraceptives do in women. Acceptability, however, is likely to vary widely among
societies, as is the case with female contraceptives.
C ONCLUSION
The number of users of contraception in the developing world is expected to rise
from 549 million to 816 million over the next 25 years according to the most recent UN
projection. An examination of the projection methodology found it to be reasonable.
The two main factors driving this increase were identified as the growth in population
size (and hence the number of women of reproductive age) and the rise in the contracep-
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tive prevalence level that will accompany further declines in fertility. The rate of growth
in users will be much more rapid in Africa than in Asia or Latin America, because growth
in both factors will be higher in Africa than elsewhere.
Projecting the future distribution of specific contraceptive methods is more difficult. Method choice is affected by trends in several factors, including access to different
methods, user characteristics, and technology. In addition, the health effects of contraceptives will become a more important consideration to women and men in the future,
because contraceptives will be used during a large proportion of the reproductive years.
We expect the mix of contraceptives to change slowly over the coming years. No new
product currently in development will radically alter the prevailing pattern. However, a
gradual increase in availability of a wider range of methods is likely as the quality of
services is improved, as markets for contraceptives become more open, and as levels of
contraceptive knowledge and education rise. This should result in a greater variety of
contraceptives in use and a more balanced distribution among different modern methods. These trends will likely favor new hormonal contraceptives, especially if their cost
can be reduced, and diminish the current heavy reliance on female sterilization.
A PPENDIX : A N A LTERNATIVE M ETHODOLOGY FOR
P ROJECTING M ETHOD M IX
We employed the following procedure to project the distribution of contraceptive
users by method from the date of the latest available survey to 2015. First, the
(unweighted) average method mix for countries with contraceptive prevalence exceeding 65 percent was calculated to represent the typical pattern at the end of the fertility
transition. This produces the following percent distribution:
Female
sterilization

Male
sterilization

Pill

Injectables

IUD

Vaginal

Condom

Traditional

Total

30.0

3.2

19.8

3.4

16.0

0.5

11.8

15.3

100.0

Next, the target distribution in 2015 for each country is determined by averaging
the observed distribution at the time of the most recent survey and the above typical
pattern. Finally, each country is moved along a linear trajectory from its current mix to
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its target mix by 2015.6 This procedure is followed for each method except traditional
ones; their proportion is assumed to be reduced in all countries to one-half the most
recently observed level by 2015, with linear interpolation for intervening years. The
proportions projected with this procedure are adjusted proportionally to ensure they add
to 100 percent.
This procedure differs from the one used by the Futures Group in that the rate of
convergence in the method mix over time is much slower (by about half on average), method
mixes vary much more among countries in 2015, all countries are treated in the same way,
and proportions of users relying on traditional methods are reduced in all countries.
To test the accuracy of this new methodology, we used it to prepare a projection
from the late 1970s to the early 1990s for each of 31 countries. The latest available
survey before 1981 provided the baseline data and the method mix was projected forward from that base to the date of the latest available survey (mostly in the 1990s). Two
sets of projections were made, one with the new procedure and the other with the Futures Group’s methodology. A comparison of the projected method mix with the observed mix provided a measure of the accuracy of the two approaches. With the new
approach the average error in the 31 countries between the projected and observed proportions using a method ranged from 9.5 percentage points for the pill to 2.0 percentage
points for male sterilization, averaging 5.6 percentage points. The comparable errors for
the Futures Group procedure were similar in magnitude, averaging 5.5 percentage points.
Although the new procedure is not more accurate in projecting past trends than the
Futures Group’s procedure in the average country, it is simpler to apply. More importantly, it avoids some large and, to us, implausible changes in method mix projected for
2015 in several of the largest countries in the developing world, including China, India,
Bangladesh, and Pakistan.
Notes
1

The value of T is actually not projected independently in most countries because
where data on prevalence among all women are available from surveys they are used
directly. The future trend in T is then calculated as the ratio of the projected number of
all users to married users and it is not the result of explicit assumptions about T.
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2

The projection equation used by the UN simplifies to TFR1/TFR2=(1–u1)/(1–u2)
if contraceptive effectiveness is assumed to equal the average level of 93 percent
(UN 1999a). In this equation TFR and u represent, respectively, the total fertility
rate and contraceptive prevalence, and the subscripts 1 and 2 refer to the beginning and end years of the projection.

3

The correlation between the proportion of users of a particular method in the
latest survey before 1981 and the same proportion in the latest available survey
(mostly in the 1990s) for the different methods ranged from 0.90 for female sterilization to 0.46 for the IUD, averaging 0.68.

4

Figure 8 gives past and estimated future dates of approval by the US Food and
Drug Administration (FDA), together with the date of first launch of a product in
the given category. FDA approval has global consequences, not only because of
the high quality of the approval process, but also because the US Agency for
International Development can purchase only FDA-approved products for distribution in developing countries.

5

These products, with the exception of Depo Provera, were originally developed
by the Population Council.

6

No specific assumptions are made about trends beyond 2015, but it seems unlikely that they will continue along the pre-2015 trajectory.
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